Come and join us across the globe
November 16, 2021, Bochum, Germany. The authors of the Diversion-p64 study 1 conclude that phenox’ p64 Flow Modulation Device has a high efficacy and demonstrates one of the lowest rates of morbidity-mortality compared to similar studies. The trial represents the largest prospective study on flow diversion to date. With 420 patients enrolled in 26 centres across 10 countries, the results provide strong evidence for maximized flow modulation effect from the 64-wire braid design of the p64 device for treating intracranial aneurysms.